



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 October 2011
EMA/CHMP/812168/2011
Committee for medicinal products for human use (CHMP)

Summary of opinion¹ (initial authorisation)

Repaglinide Accord

Repaglinide

On 20 October 2011 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion^{**}, recommending the granting of a marketing authorisation for the medicinal product Repaglinide Accord 0.5 mg, 1 mg, 2 mg tablets intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Accord Healthcare Ltd.

The active substance of Repaglinide Accord is Repaglinide, a short-acting oral secretagogue that is a carbamoylmethyl benzoid acid derivative (ATC code: A10BX02). Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β -cells in the pancreatic islets.

Repaglinide Accord is a generic of NovoNorm, which has been authorised in the EU since 17 August 1998. Studies have demonstrated the satisfactory quality of Repaglinide Accord, and its bioequivalence with Prandin. A question-and-answer document on generic medicines can be found [here](#).

The approved indication is: "Repaglinide is indicated in patients with type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals."

Detailed recommendations for the use of this product will be described in the Summary of Product Characteristics (SmPC) which will be published in the European Public Assessment Report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of the data submitted, considers that there is a favourable benefit risk balance for Repaglinide Accord, and therefore recommends the granting of the marketing authorisation.

¹ Summaries of positive opinion are published without prejudice to the commission decision, which will normally be issued 67 days from adoption of the opinion.

^{**} Applicants may request a re-examination of any CHMP opinion, provided they notify the EMA in writing of their intention to request a re-examination within 15 days of receipt of the opinion.

